Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$1.48 +2.1%	$1.62	$1.13 ▼ $2.66	$129.39M	2.61	236,550 shs	282,242 shs
KURA Kura Oncology	$6.02 -0.5%	$6.17	$5.41 ▼ $21.57	$523.78M	0.41	1.24 million shs	1.19 million shs
SLDB Solid Biosciences	$6.83 -0.1%	$5.06	$2.41 ▼ $10.37	$530.21M	2.43	1.46 million shs	1.15 million shs
UPXI Upexi	$4.60 -0.9%	$7.42	$1.90 ▼ $22.57	$414.19M	-0.58	12.72 million shs	5.52 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	+2.07%	-3.27%	-14.94%	0.00%	-16.38%
KURA Kura Oncology	-0.50%	-3.37%	+3.61%	-6.96%	-71.07%
SLDB Solid Biosciences	-0.15%	-2.43%	+40.25%	+58.47%	-23.43%
UPXI Upexi	-0.86%	-24.71%	+59.17%	-67.31%	-34.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEN Compugen	2.0068 of 5 stars	3.5	4.0	0.0	2.0	0.0	0.0
KURA Kura Oncology	3.3429 of 5 stars	3.4	1.0	4.7	0.6	0.8	0.6
SLDB Solid Biosciences	2.6741 of 5 stars	4.6	1.0	0.0	1.1	1.7	0.6
UPXI Upexi	3.769 of 5 stars	3.5	5.0	0.0	3.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEN Compugen	3.00	Buy	$4.00	170.27% Upside
KURA Kura Oncology	2.86	Moderate Buy	$24.50	306.98% Upside
SLDB Solid Biosciences	3.17	Buy	$15.10	121.08% Upside
UPXI Upexi	3.00	Buy	$16.00	247.83% Upside

Current Analyst Ratings Breakdown

Latest CGEN, UPXI, SLDB, and KURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$16.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/20/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00
6/17/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/16/2025	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$16.00
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
6/4/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/19/2025	KURA Kura Oncology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEN Compugen	$27.86M	4.74	N/A	N/A	$0.62 per share	2.39
KURA Kura Oncology	$53.88M	9.67	N/A	N/A	$5.32 per share	1.13
SLDB Solid Biosciences	$8.09M	65.44	N/A	N/A	$3.43 per share	1.99
UPXI Upexi	$16.56M	24.82	N/A	N/A	$6.24 per share	0.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEN Compugen	-$14.23M	-$0.16	N/A	N/A	N/A	-51.27%	-24.51%	-12.19%	8/6/2025 (Estimated)
KURA Kura Oncology	-$173.98M	-$2.10	N/A	N/A	N/A	N/A	-43.62%	-29.13%	8/7/2025 (Estimated)
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-68.15%	-55.33%	8/12/2025 (Estimated)
UPXI Upexi	-$23.66M	N/A	0.00	∞	N/A	-135.86%	-535.19%	-122.94%	9/29/2025 (Estimated)

Latest CGEN, UPXI, SLDB, and KURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	SLDB Solid Biosciences	-$0.51	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	KURA Kura Oncology	$0.15	N/A	N/A	N/A	$64.95 million	N/A
8/6/2025	Q2 2025	CGEN Compugen	-$0.07	N/A	N/A	N/A	$3.95 million	N/A
5/19/2025	Q1 2025	CGEN Compugen	-$0.06	-$0.08	-$0.02	-$0.08	$3.70 million	$2.28 million
5/16/2025	Q1 2025	UPXI Upexi	N/A	-$2.87	N/A	-$2.87	N/A	$3.16 million
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
UPXI Upexi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEN Compugen	N/A	5.09	5.09
KURA Kura Oncology	0.02	8.07	8.07
SLDB Solid Biosciences	N/A	10.89	10.89
UPXI Upexi	0.31	0.37	0.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEN Compugen	12.22%
KURA Kura Oncology	N/A
SLDB Solid Biosciences	81.46%
UPXI Upexi	5.68%

Insider Ownership

Company	Insider Ownership
CGEN Compugen	9.50%
KURA Kura Oncology	6.40%
SLDB Solid Biosciences	1.90%
UPXI Upexi	31.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEN Compugen	70	89.24 million	80.76 million	Optionable
KURA Kura Oncology	130	86.57 million	81.03 million	Optionable
SLDB Solid Biosciences	100	77.51 million	76.04 million	Optionable
UPXI Upexi	130	89.36 million	61.12 million	Optionable

CGEN, UPXI, SLDB, and KURA Headlines

Recent News About These Companies

Upexi, Inc. (NASDAQ:UPXI) Director Gene Salkind Buys 20,243 Shares

July 31 at 7:37 PM | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 20,243 Shares of Stock

July 31 at 6:37 AM | insidertrades.com

Upexi (NASDAQ:UPXI) Stock Price Down 9.9% - What's Next?

July 31 at 4:20 AM | marketbeat.com

Upexi to Participate in Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on August 12th-14th

July 30 at 12:14 PM | manilatimes.netM

Upexi Secures $500M Equity Deal to Buy More Solana Despite Stock Drop

July 30 at 12:14 PM | thecurrencyanalytics.comT

Upexi enters $500M equity line agreement

July 29, 2025 | msn.com

Upexi, Inc. Announces $500 Million Equity Line Agreement with A.G.P. to Accelerate the Growth of its Solana Treasury Strategy

July 29, 2025 | manilatimes.netM

Solana Treasury firm Upexi secures $500M to acquire more SOL

July 29, 2025 | msn.com

Upexi Target of Unusually High Options Trading (NASDAQ:UPXI)

July 29, 2025 | americanbankingnews.com

Upexi (NASDAQ:UPXI) Shares Gap Up - Here's Why

July 28, 2025 | marketbeat.com

Traders Buy Large Volume of Call Options on Upexi (NASDAQ:UPXI)

July 28, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 4,000 Shares of Stock

July 25, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Purchases 11,000 Shares of Stock

July 25, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) CEO Buys 161,943 Shares of Stock

July 25, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 4,000 Shares of Stock

July 25, 2025 | insidertrades.com

Upexi Purchases 83,000 SOL, Grows Treasury to 1.9 Million SOL Worth $381 Million

July 25, 2025 | manilatimes.netM

Upexi Grows Treasury to 1.819 Million SOL Worth $331 Million with a $58 Million Unrealized Gain in Under Three Months

July 21, 2025 | globenewswire.com

Upexi Shares Slump After $50M Private Placement Offering Closes

July 17, 2025 | marketwatch.com

Upexi call volume above normal and directionally bullish

July 17, 2025 | msn.com

Upexi Shares Jump After Securing $150 Million in Convertible Notes Backed by Solana

July 17, 2025 | msn.com

Upexi Announces Closing of $50 Million Private Placement Equity Offering

July 15, 2025 | manilatimes.netM

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN, UPXI, SLDB, and KURA Company Descriptions

Compugen NASDAQ:CGEN

$1.48 +0.03 (+2.07%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.50 +0.02 (+1.35%)

As of 08/1/2025 06:11 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Kura Oncology NASDAQ:KURA

$6.02 -0.03 (-0.50%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$6.02 0.00 (-0.08%)

As of 08/1/2025 05:22 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Solid Biosciences NASDAQ:SLDB

$6.83 -0.01 (-0.15%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$6.64 -0.19 (-2.71%)

As of 08/1/2025 06:33 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Upexi NASDAQ:UPXI

$4.60 -0.04 (-0.86%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$4.58 -0.01 (-0.33%)

As of 08/1/2025 07:59 PM Eastern

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time